The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
ApexOnco Front Page
Recent articles
Tecvayli and Hernexeos might get speedy approval decisions.
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
ESMO and the Triple Meeting approach.
The ESMO presidential session will feature data from Destiny-Breast05 and 11.
Genmab acquires the Dutch biotech for $8bn.
